Yunes Panahi1, Soha Namazi2, Javad Rostami-Yalmeh3, Ebrahim Sahebi3, Nahid Khalili4, Tannaz Jamialahmadi5,6, Amirhossein Sahebkar7,8,9,10. 1. Faculty of Pharmacy, Pharmacotherapy Department, Baqiyatallah University of Medical Sciences, Tehran, Iran. 2. Department of Pharmacotherapy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. namazisoha@yahoo.com. 3. Department of Pharmacotherapy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Department of Endocrinology, Baqiyatallah University of Medical Sciences, Tehran, Iran. 5. Department of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran. 6. Faculty of Medicine, Department of Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir. 8. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir. 9. School of Medicine The University of Western Australia, Perth, Australia. sahebkara@mums.ac.ir. 10. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir.
Abstract
BACKGROUND: Low serum vitamin D level is associated with both high blood pressure and incidence of primary hypertension. Experimental studies suggest that vitamin D supplements may reduce blood pressure. OBJECTIVE: The aim of this study was to investigate whether vitamin D supplementation reduces systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) in Iranian patients with essential hypertension. METHOD: A total of 173 patients with essential hypertension participated in this open-label clinical trial. SBP, DBP, and serum vitamin D levels were measured at baseline and at the end of the study. Vitamin D was administered at a dose of 50,000 IU/week, and 1000 IU/day in patients with serum vitamin D levels <20 ng/mL and 20-30 ng/mL, respectively, for 8 weeks. RESULTS: Based on serum vitamin D levels, 45.1%, 17.3%, and 29.5% of patients were deficient, insufficient, and sufficient for vitamin D intake, respectively. Baseline serum levels of vitamin D were not correlated with SBP, DBP, and MAP at the beginning of the study (p = ns). Multiple logistic regression analysis revealed that the risk of vitamin D deficiency was 2.5-fold times higher in women than in men (p = 0.03). After 8 weeks of supplementation with vitamin D, mean SBP and MAP were significantly reduced by 5.5 ± 16.16 (p = 0.01) and 3.7 ± 9.24 (p = 0.004) mmHg, respectively. Neither sex nor age could significantly predict BP response to vitamin D supplementation. CONCLUSION: Vitamin D supplementation may significantly reduce SBP and MAP but not DBP in patients with essential hypertension.
BACKGROUND: Low serum vitamin D level is associated with both high blood pressure and incidence of primary hypertension. Experimental studies suggest that vitamin D supplements may reduce blood pressure. OBJECTIVE: The aim of this study was to investigate whether vitamin D supplementation reduces systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) in Iranian patients with essential hypertension. METHOD: A total of 173 patients with essential hypertension participated in this open-label clinical trial. SBP, DBP, and serum vitamin D levels were measured at baseline and at the end of the study. Vitamin D was administered at a dose of 50,000 IU/week, and 1000 IU/day in patients with serum vitamin D levels <20 ng/mL and 20-30 ng/mL, respectively, for 8 weeks. RESULTS: Based on serum vitamin D levels, 45.1%, 17.3%, and 29.5% of patients were deficient, insufficient, and sufficient for vitamin D intake, respectively. Baseline serum levels of vitamin D were not correlated with SBP, DBP, and MAP at the beginning of the study (p = ns). Multiple logistic regression analysis revealed that the risk of vitamin D deficiency was 2.5-fold times higher in women than in men (p = 0.03). After 8 weeks of supplementation with vitamin D, mean SBP and MAP were significantly reduced by 5.5 ± 16.16 (p = 0.01) and 3.7 ± 9.24 (p = 0.004) mmHg, respectively. Neither sex nor age could significantly predict BP response to vitamin D supplementation. CONCLUSION: Vitamin D supplementation may significantly reduce SBP and MAP but not DBP in patients with essential hypertension.
Authors: John P Forman; Edward Giovannucci; Michelle D Holmes; Heike A Bischoff-Ferrari; Shelley S Tworoger; Walter C Willett; Gary C Curhan Journal: Hypertension Date: 2007-03-19 Impact factor: 10.190
Authors: Thomas J Wang; Michael J Pencina; Sarah L Booth; Paul F Jacques; Erik Ingelsson; Katherine Lanier; Emelia J Benjamin; Ralph B D'Agostino; Myles Wolf; Ramachandran S Vasan Journal: Circulation Date: 2008-01-07 Impact factor: 29.690
Authors: Emin Murat Akbas; Adem Gungor; Adalet Ozcicek; Nergis Akbas; Seda Askin; Murat Polat Journal: Arch Med Sci Date: 2016-07-01 Impact factor: 3.318